EMV
data caveat$172MCF+
Emvision Medical Devices
Neurology
Strokefinder portable MRI device for rapid stroke triage at point of care
Data HealthFiling4C overdue · Dec 202580dTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$18.4M
Mar 2026 4C
Runway
CF+Cash Flow Positive
Based on Mar 2026 4C
Market Cap
$172M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
93M
Pipeline Assets
2
Latest Insight(1)
12 Apr 2026Quarterly 4CQuarterly Activities/Appendix 4C Cash Flow Report
Cash$18.4M·Burn$0.9M/q·OCF$0.9M·RDTI$3.8M
3M Price
EMV.ASX$1.850+4.5% 3M
Low $1.530High $1.850
Pipeline Assets (2)
emu First Responderstroke (pre-hospital)
Phase 1emuintracranial hemorrhage (stroke)
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
emu First Responder
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
R&D Tax Incentive
$3.8M received43.5% ATO refund
FY2026received
Auto-extracted from 4C (2026-03-31)
$3.80M
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as estimated or registeredare forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Competitive Landscape
24 competitor trialsPhase 2+ · Non-ASX
Stroke (Pre-Hospital)3 active trials
2 Ph31 Ph2
Intracranial Hemorrhage (Stroke)21 active trials
5 Ph49 Ph31 Ph2/36 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (1)
SpeculativeremoveMed1 Nov 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| Trial data readout — Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detectionopen_in_new Primary completion expected for NCT06999122. Indication: {Stroke,"Hemorrhagic Stroke"} | data readout | Speculative | removeMed |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 1/2 quarters with positive operating cash flow
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
1 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 392d
Brain Scan
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
Stroke · Hemorrhagic Stroke
22 Years+
Primary endpoint Demonstrate haemorrhage detection sensitivity >80% and specificity >80%
Announcements(7)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report12 Apr 2026
expand_more285KB